Toshimitsu Hamasaki
George Washington University
H-index: 50
North America-United States
Top articles of Toshimitsu Hamasaki
Exploration of a Potential DOOR Endpoint for Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia Using Six Registrational Trials for …
Clinical Infectious Diseases
2024/3/25
Moving beyond mortality: development and application of a desirability of outcome ranking (DOOR) endpoint for hospital-acquired bacterial pneumonia and ventilator-associated …
Clinical Infectious Diseases
2024/2/15
Jessica Howard-Anderson
H-Index: 4
Toshimitsu Hamasaki
H-Index: 34
The DOOR is open: A Web-based Application for Analyzing the Desirability of Outcome Ranking
Open Forum Infectious Diseases
2023/12
Toshimitsu Hamasaki
H-Index: 34
The Future Ain’t What It Used to Be… Out With the Old… In With the Better: Antibacterial Resistance Leadership Group Innovations
Clinical Infectious Diseases
2023/10/15
Toshimitsu Hamasaki
H-Index: 34
Jessica Howard-Anderson
H-Index: 4
Under the Hood: The Scientific Leadership, Clinical Operations, Statistical and Data Management, and Laboratory Centers of the Antibacterial Resistance Leadership Group
Clinical Infectious Diseases
2023/10/15
Maria Souli
H-Index: 29
Toshimitsu Hamasaki
H-Index: 34
Priorities and Progress in Gram-positive Bacterial Infection Research by the Antibacterial Resistance Leadership Group: A Narrative Review
2023/10/15
Ahmed Babiker
H-Index: 11
Toshimitsu Hamasaki
H-Index: 34
Brendan J Kelly
H-Index: 10
Nicholas A Turner
H-Index: 9
Priorities and progress in gram-negative bacterial infection research by the antibacterial resistance leadership group
Clinical Infectious Diseases
2023/10/15
David Van Duin
H-Index: 38
Daria Van Tyne
H-Index: 17
Nadine Rouphael
H-Index: 28
Toshimitsu Hamasaki
H-Index: 34
Maria Souli
H-Index: 29
Yohei Doi
H-Index: 54
Exploration of a potential desirability of outcome ranking endpoint for complicated intra-abdominal infections using 9 registrational trials for antibacterial drugs
Clinical Infectious Diseases
2023/8/15
Scott Evans
H-Index: 9
Toshimitsu Hamasaki
H-Index: 34
Jessica Howard-Anderson
H-Index: 4
Peter Kim
H-Index: 7
Editor’s Note: Special Section on Estimands, Design and Analysis of Clinical Trials with Time-to-Event Outcomes
2023/4/3
Toshimitsu Hamasaki
H-Index: 34
Statistics in Biopharmaceutical Research Best Papers Award 2023
2023/4/3
Toshimitsu Hamasaki
H-Index: 34
Efficacy and safety of azithromycin versus placebo to treat lower respiratory tract infections associated with low procalcitonin: a randomised, placebo-controlled, double-blind …
The Lancet Infectious Diseases
2023/4/1
Geeta K Swamy
H-Index: 32
Toshimitsu Hamasaki
H-Index: 34
David L Roberts
H-Index: 26
Matthew H Collins
H-Index: 17
Laura Oh
H-Index: 6
Zhihong Yuan
H-Index: 10
Generalized fiducial inference for the restricted mean survival time
Statistical Methods in Medical Research
2023/3/28
Guoqing Diao
H-Index: 11
Toshimitsu Hamasaki
H-Index: 34
Editor’s Note: Special Section on a Collection of Articles on Opportunities and Challenges in Utilizing Real-World Data for Clinical Trials and Medical Product Development
2023/1/2
Toshimitsu Hamasaki
H-Index: 34
Development and Analysis of a Novel DOOR Endpoint for Complicated Intra-abdominal Infections (cIAI) Using 10 Registrational Trials for Antibacterial Drugs
Open Forum Infectious Diseases
2022/12
Weighing Evidence: Robustness vs Quantity
JNCI: Journal of the National Cancer Institute
2022/9/26
Toshimitsu Hamasaki
H-Index: 34
Improving Traditional Registrational Trial End Points: Development and Application of a Desirability of Outcome Ranking End Point for Complicated Urinary Tract Infection …
Clinical Infectious Diseases
2023/2/1
Jessica Howard-Anderson
H-Index: 4
Toshimitsu Hamasaki
H-Index: 34
Editor's note
Journal of Managed Care & Specialty Pharmacy
2020/6/1
A Desirability of Outcome Ranking Analysis of a Randomized Clinical Trial Comparing Seven Versus Fourteen Days of Antibiotics for Uncomplicated Gram-Negative Bloodstream Infection
Open forum infectious diseases
2022/6/1
Dalbavancin as an option for treatment of S. aureus bacteremia (DOTS): study protocol for a phase 2b, multicenter, randomized, open-label clinical trial
Trials
2022/5/16
Nicholas A Turner
H-Index: 9
Heather King
H-Index: 13
Scott Evans
H-Index: 9
Toshimitsu Hamasaki
H-Index: 34
Bridging therapy with heparin before starting rivaroxaban in ischemic stroke or transient ischemic attack with non-valvular atrial fibrillation
Circulation Journal
2022/5
Toshimitsu Hamasaki
H-Index: 34
